Publication

New approaches and consequences for elderly cancer patients with focus on melanoma

van den Brom, R. R. H., 2017, [Groningen]: Rijksuniversiteit Groningen. 186 p.

Research output: ThesisThesis fully internal (DIV)

Copy link to clipboard

Documents

  • Title and contents

    Final publisher's version, 237 KB, PDF document

  • Chapter 1

    Final publisher's version, 394 KB, PDF document

  • Chapter 2

    Final publisher's version, 732 KB, PDF document

  • Chapter 3

    Final publisher's version, 806 KB, PDF document

  • Chapter 4

    Final publisher's version, 842 KB, PDF document

  • Chapter 5

    Final publisher's version, 745 KB, PDF document

  • Chapter 6

    Final publisher's version, 704 KB, PDF document

  • Chapter 7

    Final publisher's version, 664 KB, PDF document

  • Chapter 8a

    Final publisher's version, 358 KB, PDF document

  • Chapter 8b

    Final publisher's version, 330 KB, PDF document

    Embargo ends: 01/01/9999

  • Publisher version Chapter 8b

    Final publisher's version, 61.8 KB, PDF document

  • Chapter 8c

    Final publisher's version, 514 KB, PDF document

  • Chapter 8d

    Final publisher's version, 384 KB, PDF document

  • Chapter 8e

    Final publisher's version, 520 KB, PDF document

  • Chapter 9 (Summary)

    Final publisher's version, 488 KB, PDF document

  • Chapter 10 (Summary in Dutch)

    Final publisher's version, 570 KB, PDF document

  • Dankwoord (Acknowledgements)

    Final publisher's version, 522 KB, PDF document

  • Complete thesis

    Final publisher's version, 2.83 MB, PDF document

    Embargo ends: 01/01/9999

  • Propositions

    Final publisher's version, 84.2 KB, PDF document

  • Rob Roel Henry van den Brom
- We present modified NCCN evidence blocks to classify clinical benefit for elderly metastatic renal cell carcinoma patients.
- The efficacy of newly registered therapies for metastatic melanoma obtained high scores for clinical effect and underscores the relevance to seriously consider these novel treatment approaches in the elderly.
- The CD4+ T cell compartment of young melanoma patients shows strong signs of activation, whereas these signs are lacking in CD4+ T cells of old melanoma patients.
- A Dutch registry demonstrates that treatment with ipilimumab for metastatic melanoma is equally effective in elderly and younger patients, is safe in patients ≥ 65 years and has similar efficacy and toxicity for both genders.
- Early development of hypophosphatemia during imatinib treatment does not predict treatment efficacy.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
Supervisors/Advisors
Award date25-Sep-2017
Place of Publication[Groningen]
Publisher
Print ISBNs978-94-034-0081-5
Electronic ISBNs978-94-034-0080-8
Publication statusPublished - 2017

Download statistics

No data available

ID: 47546626